We demonstrated that treatment of in vitro epidermis models with the TLR2 agonist Pam2CSK4 and the TLR3 agonist poly(I:C) induced the expression of the psoriasis marker S100A7 (Figure 1). Here, S100A7 is linked to psoriasis.